Recombinant Human APOC2 293 Cell Lysate
Cat.No. : | APOC2-8783HCL |
- Specification
- Gene Information
- Related Products
- Download
Description : | Antigen standard for apolipoprotein C-II (APOC2) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection. |
Source : | HEK 293 cells |
Species : | Human |
Components : | This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol). |
Size : | 0.1 mg |
Storage Instruction : | Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment. |
Applications : | ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane. |
Gene Name : | APOC2 apolipoprotein C-II [ Homo sapiens ] |
Official Symbol : | APOC2 |
Synonyms : | APOC2; apolipoprotein C-II; apolipoprotein C2; APO-CII; APOC-II; MGC75082; |
Gene ID : | 344 |
mRNA Refseq : | NM_000483 |
Protein Refseq : | NP_000474 |
MIM : | 608083 |
UniProt ID : | P02655 |
Chromosome Location : | 19q13.2 |
Pathway : | Chylomicron-mediated lipid transport, organism-specific biosystem; HDL-mediated lipid transport, organism-specific biosystem; Lipid digestion, mobilization, and transport, organism-specific biosystem; Lipoprotein metabolism, organism-specific biosystem; Metabolism, organism-specific biosystem; Metabolism of lipids and lipoproteins, organism-specific biosystem; Statin Pathway, organism-specific biosystem; |
Function : | enzyme activator activity; lipase inhibitor activity; lipid binding; lipoprotein lipase activator activity; phospholipase activator activity; phospholipase binding; protein homodimerization activity; |
Products Types
◆ Recombinant Protein | ||
APOC2-634M | Recombinant Mouse APOC2 Protein, His (Fc)-Avi-tagged | +Inquiry |
Apoc2-222R | Recombinant Rat Apoc2 Protein, His-tagged | +Inquiry |
APOC2-221H | Recombinant Human APOC2 Protein, His&GST-tagged | +Inquiry |
APOC2-54C | Recombinant Cynomolgus Monkey APOC2 Protein, His (Fc)-Avi-tagged | +Inquiry |
APOC2-362H | Recombinant Human APOC2 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Native Protein | ||
APOC2-27332TH | Native Human APOC2 | +Inquiry |
APOC2-27331TH | Native Human APOC2 protein | +Inquiry |
APOC2-4904H | Native Human Apolipoprotein CII | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (24)
Ask a questionWithout functional APOC2 protein, the activation of lipoprotein lipase is compromised, leading to elevated levels of triglycerides in the blood, a condition known as hypertriglyceridemia.
Regular exercise has been shown to improve lipid metabolism and positively affect APOC2 protein activity, resulting in lower triglyceride levels in the blood.
Yes, mutations or deficiencies in the APOC2 gene can lead to various lipid metabolism disorders, including familial hypercholesterolemia and familial chylomicronemia syndrome.
Yes, variations or mutations in the APOC2 gene can affect the structure or function of the APOC2 protein, leading to altered lipid metabolism and potentially causing lipid-related disorders.
High-fat diets and excessive consumption of saturated fats are known to influence APOC2 protein activity and triglyceride levels in the body.
Yes, targeting APOC2 protein has been explored as a potential therapeutic strategy for the treatment of hypertriglyceridemia and related disorders. Inhibitors or modulators of APOC2 protein activity are currently under investigation.
Some natural compounds, such as omega-3 fatty acids and polyphenols found in certain foods, have been reported to modulate APOC2 protein activity and lipid metabolism. However, more research is required to fully understand their effects and establish appropriate dosage recommendations.
Currently, there are no medications specifically approved for targeting APOC2 protein. However, certain lipid-lowering medications, such as fibrates and omega-3 fatty acid supplements, indirectly affect APOC2 protein activity by modulating lipid metabolism.
Yes, APOC2 protein levels can be measured in blood samples using immunoassays.
Yes, genetic tests can be used to screen for mutations in the APOC2 gene, particularly in individuals with a family history of lipid metabolism disorders. These tests can help identify individuals at risk and guide treatment options.
Yes, researchers are studying the role of APOC2 in lipid metabolism disorders and exploring potential therapeutic strategies targeting this protein. Additionally, some studies are investigating the use of APOC2-modulating therapies for the treatment of hypertriglyceridemia.
APOC2 protein levels have been associated with increased risk of cardiovascular diseases, particularly hypertriglyceridemia-associated conditions. However, further research is needed to establish its utility as a reliable biomarker.
Apart from its role in lipid metabolism, the APOC2 protein has been implicated in inflammation, immune response, and cell proliferation processes, although further research is needed to fully understand these functions.
The potential side effects of APOC2-targeting therapies or interventions may vary depending on the specific treatment approach. However, some common side effects associated with lipid-lowering medications or interventions include gastrointestinal issues, muscle pain, liver problems, and allergic reactions. It is essential to consult with a healthcare professional for personalized information and guidance.
Yes, there are rare genetic disorders associated with APOC2 protein, such as familial chylomicronemia syndrome (FCS) and lipoprotein lipase deficiency (LPLD), which result in severe hypertriglyceridemia.
Yes, some medications, such as fibrates and omega-3 fatty acids, can help regulate APOC2 protein activity and reduce triglyceride levels in individuals with hypertriglyceridemia.
Studies have suggested a potential association between APOC2 protein and obesity, as higher levels of APOC2 have been observed in individuals with obesity, contributing to elevated triglyceride levels.
Elevated levels of triglycerides, caused by dysfunction of APOC2 protein, have been associated with an increased risk of cardiovascular diseases such as coronary artery disease and atherosclerosis.
APOC2 gene therapy is being explored as a potential treatment for certain lipid metabolism disorders, aiming to correct genetic mutations or deficiencies in the APOC2 gene and restore normal protein function. However, this approach is still in the experimental stages and requires further research.
There are several support groups and resources available for individuals and families affected by lipid metabolism disorders, including those associated with APOC2 abnormalities. These organizations provide information, advocacy, and support to help individuals navigate their conditions. Examples include the National Lipid Association and the National Organization for Rare Disorders (NORD).
The APOC2 protein is synthesized in the liver and intestine.
APOC2 protein interacts with various proteins and lipoproteins, including apolipoprotein C-III (APOC3) and apolipoprotein E (APOE), to regulate lipid metabolism and transport.
Yes, lifestyle modifications, including a healthy diet and regular physical activity, play a crucial role in managing APOC2-related disorders. These interventions can help control lipid levels and improve overall cardiovascular health. However, they may not be sufficient as standalone treatments, and medical interventions may be necessary in some cases.
APOC2 gene mutations are relatively rare in the general population. They are typically inherited in an autosomal recessive manner, meaning that individuals need to inherit mutated copies of the APOC2 gene from both parents to develop the associated disorders.
Customer Reviews (4)
Write a reviewThe APOC2 protein offered by the manufacturer exhibits exceptional quality and is precisely tailored to meet my experimental requirements.
Its purity, stability, and functionality make it an ideal choice for my research endeavors.
In addition to the remarkable quality of the protein, the manufacturer's support extends beyond the provision of the product itself.
With their meticulous documentation and support, I am confident that my utilization of APOC2 protein in clinical trials will meet all necessary regulations and guidelines.
Ask a Question for All APOC2 Products
Required fields are marked with *
My Review for All APOC2 Products
Required fields are marked with *
Inquiry Basket